Using iPSC-Derived Hepatocyte Models for Disease Modeling and Predictive Toxicology Screening

In early-stage drug discovery, in vitro models are essential for generating clinically relevant data that expedite the progress of potential therapeutics into clinical trials. However, most therapeutics fail long before they enter the clinic due to the lack of translatability between preclinical models and patients.

This is an important problem in liver disease—a rising cause of mortality worldwide. Current drug studies rely on primary human hepatocytes (PHH) and hepatocellular cancer cells (e.g. HepG2). However, these cells have limitations, including short lifespan, rapid loss of function, and malignant origin. Hepatocytes derived from induced pluripotent stem cells (iPSCs) successfully overcome these challenges and provide a sustainable in vitro platform for large-scale preclinical drug studies.

In this GEN webinar, our speakers will present new research into iPSC-derived hepatocyte models, how they compare to liver cancer cells lines, and why they are a better model for large-scale preclinical drug studies. During the webinar, you’ll learn about DefiniGEN’s highly characterized iPSC-derived hepatocytes (Opti-HEP) and how they provide a sustainable in vitro platform for disease modeling, ADME, and toxicology screening.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.